6 PFU/mL)的病毒液進(jìn)行造模。造模第7天,處死所有小鼠。酶聯(lián)免疫吸附法(Elisa)檢測血清NLRP3、白介素(IL)-1β和IL-18炎癥因子。結(jié)果 模型組NLRP3、IL-1β和IL-18表達(dá)水平分別為(26.43±4.14)、(31.25±5.63)、(38.57±6.45) μg/L,顯著高于對照組的(4.53±1.06)、(6.35±1.24)、(7.83±1.36) μg/L(P<0.01)。模型組心肌炎評分為(2.36±0.27)分,顯著高于對照組的(0.18±0.04)分(P<0.01)。模型組心肌細(xì)胞NLRP3表達(dá)評分為(1.82±0.24)分,顯著高于對照組的(0.16±0.03)分(P<0.01)。相關(guān)性分析顯示模型鼠NLRP3與體質(zhì)量呈顯著負(fù)相關(guān)(r=-0.517,P<0.05),和心肌炎評分呈顯著正相關(guān)(r=0.624,P<0.05)。結(jié)論 NLRP3炎癥小體可能參與了柯薩奇B組3型病毒致小鼠病毒性心肌炎的的發(fā)生過程。;Objective To detect the role of NLRP3 in coxsackievirus induced viral myocarditis. Methods Forty BALB/c male mice aged 6 一 8 weeks were randomly divided into control and viral myocarditis model groups, each group had 20 mice. The control group were ip 0.1 mL normal saline, and the model group were ip containing CVB3 virus (1×106 PFU/mL) virus solution for modeling. On the 7th day, all mice were killed. Elisa was used to detect serum NLRP3, IL-1β, and IL-18 inflammatory factors. Results The expression levels of NLRP3, IL-1β and IL-18 in model group were (26.43 ±4.14), (31.25 ±5.63) and (38.57 ±6.45) μg/L, which was significantly higher than that of (4.53 ±1.06), (6.35 ±1.24) and (7.83 ±1.36) μg/L in control group (P<0.01). The myocarditis score of model group was (2.36 ±0.27), which was significantly higher than that of (0.18 ±0.04) in control group (P<0.01). The NLRP3 score of model group was (1.82 ±0.24), which was significantly higher than that of (0.16 ±0.03) in control group (P<0.01). NLRP3 was negatively correlated with body weight (r=-0.517, P<0.05) and positively correlated with myocarditis score (r=0.624, P<0.05). Conclusion NLRP3 inflammatory bodies may be involved in the pathogenesis and development of viral myocarditis in mice induced by Coxsackie B virus type 3."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2019年第42卷第12期 >2019,42(12):2360-2363. DOI:10.7501/j.issn.1674-6376.2019.12.013
上一篇 | 下一篇

核苷酸結(jié)合寡聚化結(jié)構(gòu)域樣受體蛋白3在病毒性心肌炎中的作用研究

Role of NLRP3 in viral myocarditis

發(fā)布日期:2020-01-19
您是第位訪問者
藥物評價研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號:(津)-非經(jīng)營性-2015-0031